Protein Engineering Market: Global Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Protein Engineering Market: By Product Type ( Vaccines, Biologics) Technology (Rational Protein Design, Directed Evolution, Hybrid Approach) End User (Biopharmaceutical Companies, Academic Research Institutes, Contract Research Organizations (CROs)) and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

1. Executive Summary
2. Global Protein Engineering Market Introduction
2.1. Global Protein Engineering Market – Taxonomy
2.2. Global Protein Engineering Market –Definitions
2.2.1. Product Product Type
2.2.2. Technology
2.2.3. End User
2.2.4. Region
3. Global Protein Engineering Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Protein Engineering Market Dynamic Factors – Impact Analysis
3.6. Impact of COVID 19 on The Market
3.7. Three Forecast Scenarios – Pessimistic, Conservative and Opportunistic
3.8. Mapping Market Players Activities
3.9. Recent Key Developments
3.10. Financial Status of the Market Players
3.11. Recent Acquisitions, Collaborations and Mergers
4. Global Protein Engineering Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Protein Engineering Market Forecast, By Product Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1. Vaccines
5.1.1. Live-attenuated Vacciness
5.1.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. Inactivated Vacciness
5.1.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.1.3. Recombinant protein Vacciness
5.1.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3.3. Market Opportunity Analysis
5.1.4. Polysaccharide-based Vacciness
5.1.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.4.3. Market Opportunity Analysis
5.1.5. Messenger RNA Vacciness
5.1.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.5.3. Market Opportunity Analysis
5.2. Biologics
5.2.1. Hormones
5.2.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.1.3. Market Opportunity Analysis
5.2.2. Blood Products
5.2.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.2.3. Market Opportunity Analysis
5.2.3. Cytokines
5.2.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3.3. Market Opportunity Analysis
5.2.4. Growth Factors
5.2.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.4.3. Market Opportunity Analysis
5.2.5. Fusion Proteins
5.2.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.5.3. Market Opportunity Analysis
5.2.6.  Gene and Cellular Therapies
5.2.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.6.3. Market Opportunity Analysis
5.2.7. Insulin
5.2.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.7.3. Market Opportunity Analysis
5.2.8. Interferons
5.2.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.8.3. Market Opportunity Analysis
5.2.9. Monoclonal Antibody
5.2.9.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.9.3. Market Opportunity Analysis
6. Global Protein Engineering Market Forecast, By Technology, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1. Rational Protein Design
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Directed Evolution
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Hybrid Approach
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Protein Engineering Market Forecast, By End User, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1. Biopharmaceutical Companies
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Academic Research Institutes
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Contract Research Organizations (CROs)
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Protein Engineering Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1. North America
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Protein Engineering Market – Opportunity Analysis Index, By Product Type, Technology, End User, and Region, 2022 – 2028
9. North America Protein Engineering Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.1.1. Vaccines
9.1.1.1. Live-attenuated Vacciness
9.1.1.2. Inactivated Vacciness
9.1.1.3. Recombinant protein Vacciness
9.1.1.4. Polysaccharide-based Vacciness
9.1.1.5. Messenger RNA Vacciness
9.1.2. Biologics
9.1.2.1. Hormones
9.1.2.2. Blood Products
9.1.2.3. Cytokines
9.1.2.4. Growth Factors
9.1.2.5. Fusion Proteins
9.1.2.6.  Gene and Cellular Therapies
9.1.2.7. Insulin
9.1.2.8. Interferon
9.1.2.9. Monoclonal Antibody
9.2. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Rational Protein Design
9.2.2. Directed Evolution
9.2.3. Hybrid Approach
9.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Biopharmaceutical Companies
9.3.2. Academic Research Institutes
9.3.3. Contract Research Organizations (CROs)
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Protein Engineering Market – Opportunity Analysis Index, By Product Type, Technology, End User, and Country, 2022 – 2028
9.6. North America Protein Engineering Market Dynamics – Trends
10. Europe Protein Engineering Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
10.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.1.1. Vaccines
10.1.1.1. Live-attenuated Vacciness
10.1.1.2. Inactivated Vacciness
10.1.1.3. Recombinant protein Vacciness
10.1.1.4. Polysaccharide-based Vacciness
10.1.1.5. Messenger RNA Vacciness
10.1.2. Biologics
10.1.2.1. Hormones
10.1.2.2. Blood Products
10.1.2.3. Cytokines
10.1.2.4. Growth Factors
10.1.2.5. Fusion Proteins
10.1.2.6.  Gene and Cellular Therapies
10.1.2.7. Insulin
10.1.2.8. Interferon
10.1.2.9. Monoclonal Antibody
10.2. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Rational Protein Design
10.2.2. Directed Evolution
10.2.3. Hybrid Approach
10.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Biopharmaceutical Companies
10.3.2. Academic Research Institutes
10.3.3. Contract Research Organizations (CROs)
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Protein Engineering Market – Opportunity Analysis Index, By Product Type, Technology, End User, and Country, 2022 – 2028
10.6. Europe Protein Engineering Market Dynamics – Trends
11. Asia-Pacific Protein Engineering Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
11.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.1.1. Vaccines
11.1.1.1. Live-attenuated Vacciness
11.1.1.2. Inactivated Vacciness
11.1.1.3. Recombinant protein Vacciness
11.1.1.4. Polysaccharide-based Vacciness
11.1.1.5. Messenger RNA Vacciness
11.1.2. Biologics
11.1.2.1. Hormones
11.1.2.2. Blood Products
11.1.2.3. Cytokines
11.1.2.4. Growth Factors
11.1.2.5. Fusion Proteins
11.1.2.6.  Gene and Cellular Therapies
11.1.2.7. Insulin
11.1.2.8. Interferon
11.1.2.9. Monoclonal Antibody
11.2. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Rational Protein Design
11.2.2. Directed Evolution
11.2.3. Hybrid Approach
11.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Biopharmaceutical Companies
11.3.2. Academic Research Institutes
11.3.3. Contract Research Organizations (CROs)
11.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Rest of Asia-Pacific
11.5. Asia-Pacific Protein Engineering Market – Opportunity Analysis Index, By Product Type, Technology, End User, and Country, 2022 – 2028
11.6. Asia-Pacific Protein Engineering Market Dynamics – Trends
12. Latin America Protein Engineering Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
12.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.1.1. Vaccines
12.1.1.1. Live-attenuated Vacciness
12.1.1.2. Inactivated Vacciness
12.1.1.3. Recombinant protein Vacciness
12.1.1.4. Polysaccharide-based Vacciness
12.1.1.5. Messenger RNA Vacciness
12.1.2. Biologics
12.1.2.1. Hormones
12.1.2.2. Blood Products
12.1.2.3. Cytokines
12.1.2.4. Growth Factors
12.1.2.5. Fusion Proteins
12.1.2.6.  Gene and Cellular Therapies
12.1.2.7. Insulin
12.1.2.8. Interferon
12.1.2.9. Monoclonal Antibody
12.2. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Rational Protein Design
12.2.2. Directed Evolution
12.2.3. Hybrid Approach
12.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Biopharmaceutical Companies
12.3.2. Academic Research Institutes
12.3.3. Contract Research Organizations (CROs)
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Argentina
12.4.3. Rest of Latin America
12.5. Latin America Protein Engineering Market – Opportunity Analysis Index, By Product Type, Technology, End User, and Country, 2022 – 2028
12.6. Latin America Protein Engineering Market Dynamics – Trends
13. Middle East and Africa Protein Engineering Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
13.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.1.1. Vaccines
13.1.1.1. Live-attenuated Vacciness
13.1.1.2. Inactivated Vacciness
13.1.1.3. Recombinant protein Vacciness
13.1.1.4. Polysaccharide-based Vacciness
13.1.1.5. Messenger RNA Vacciness
13.1.2. Biologics
13.1.2.1. Hormones
13.1.2.2. Blood Products
13.1.2.3. Cytokines
13.1.2.4. Growth Factors
13.1.2.5. Fusion Proteins
13.1.2.6.  Gene and Cellular Therapies
13.1.2.7. Insulin
13.1.2.8. Interferon
13.1.2.9. Monoclonal Antibody
13.2. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Rational Protein Design
13.2.2. Directed Evolution
13.2.3. Hybrid Approach
13.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Biopharmaceutical Companies
13.3.2. Academic Research Institutes
13.3.3. Contract Research Organizations (CROs)
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Saudi Arabia
13.4.2. GCC Countries
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Protein Engineering Market – Opportunity Analysis Index, By Product Type, Technology, End User, and Country, 2022 – 2028
13.6. MEA Protein Engineering Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product Type Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. GE Healthcare
14.2.2. Codexis, Inc.
14.2.3. Agilent Technologies, Inc.
14.2.4. Thermo Fisher Scientific, Inc.
14.2.5. Agilent Technologies, Inc.
14.2.6. Danaher Corporation
14.2.7. Abzena Ltd.
14.2.8. Genscript Biotech Corporation
14.2.9. Bio-Rad Laboratories
14.2.10. Sanofi
15. Research Methodology
16. Key Assumptions and Acronyms

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Company Profile

  • GE Healthcare
  • Codexis, Inc.
  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific, Inc.
  • Agilent Technologies, Inc.
  • Danaher Corporation
  • Abzena Ltd.
  • Genscript Biotech Corporation
  • Bio-Rad Laboratories
  • Sanofi

Description

1. Executive Summary
2. Global Protein Engineering Market Introduction
2.1. Global Protein Engineering Market – Taxonomy
2.2. Global Protein Engineering Market –Definitions
2.2.1. Product Product Type
2.2.2. Technology
2.2.3. End User
2.2.4. Region
3. Global Protein Engineering Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Protein Engineering Market Dynamic Factors – Impact Analysis
3.6. Impact of COVID 19 on The Market
3.7. Three Forecast Scenarios – Pessimistic, Conservative and Opportunistic
3.8. Mapping Market Players Activities
3.9. Recent Key Developments
3.10. Financial Status of the Market Players
3.11. Recent Acquisitions, Collaborations and Mergers
4. Global Protein Engineering Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Protein Engineering Market Forecast, By Product Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1. Vaccines
5.1.1. Live-attenuated Vacciness
5.1.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. Inactivated Vacciness
5.1.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.1.3. Recombinant protein Vacciness
5.1.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3.3. Market Opportunity Analysis
5.1.4. Polysaccharide-based Vacciness
5.1.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.4.3. Market Opportunity Analysis
5.1.5. Messenger RNA Vacciness
5.1.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.5.3. Market Opportunity Analysis
5.2. Biologics
5.2.1. Hormones
5.2.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.1.3. Market Opportunity Analysis
5.2.2. Blood Products
5.2.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.2.3. Market Opportunity Analysis
5.2.3. Cytokines
5.2.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3.3. Market Opportunity Analysis
5.2.4. Growth Factors
5.2.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.4.3. Market Opportunity Analysis
5.2.5. Fusion Proteins
5.2.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.5.3. Market Opportunity Analysis
5.2.6.  Gene and Cellular Therapies
5.2.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.6.3. Market Opportunity Analysis
5.2.7. Insulin
5.2.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.7.3. Market Opportunity Analysis
5.2.8. Interferons
5.2.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.8.3. Market Opportunity Analysis
5.2.9. Monoclonal Antibody
5.2.9.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.9.3. Market Opportunity Analysis
6. Global Protein Engineering Market Forecast, By Technology, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1. Rational Protein Design
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Directed Evolution
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Hybrid Approach
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Protein Engineering Market Forecast, By End User, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1. Biopharmaceutical Companies
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Academic Research Institutes
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Contract Research Organizations (CROs)
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Protein Engineering Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1. North America
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Protein Engineering Market – Opportunity Analysis Index, By Product Type, Technology, End User, and Region, 2022 – 2028
9. North America Protein Engineering Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.1.1. Vaccines
9.1.1.1. Live-attenuated Vacciness
9.1.1.2. Inactivated Vacciness
9.1.1.3. Recombinant protein Vacciness
9.1.1.4. Polysaccharide-based Vacciness
9.1.1.5. Messenger RNA Vacciness
9.1.2. Biologics
9.1.2.1. Hormones
9.1.2.2. Blood Products
9.1.2.3. Cytokines
9.1.2.4. Growth Factors
9.1.2.5. Fusion Proteins
9.1.2.6.  Gene and Cellular Therapies
9.1.2.7. Insulin
9.1.2.8. Interferon
9.1.2.9. Monoclonal Antibody
9.2. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Rational Protein Design
9.2.2. Directed Evolution
9.2.3. Hybrid Approach
9.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Biopharmaceutical Companies
9.3.2. Academic Research Institutes
9.3.3. Contract Research Organizations (CROs)
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Protein Engineering Market – Opportunity Analysis Index, By Product Type, Technology, End User, and Country, 2022 – 2028
9.6. North America Protein Engineering Market Dynamics – Trends
10. Europe Protein Engineering Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
10.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.1.1. Vaccines
10.1.1.1. Live-attenuated Vacciness
10.1.1.2. Inactivated Vacciness
10.1.1.3. Recombinant protein Vacciness
10.1.1.4. Polysaccharide-based Vacciness
10.1.1.5. Messenger RNA Vacciness
10.1.2. Biologics
10.1.2.1. Hormones
10.1.2.2. Blood Products
10.1.2.3. Cytokines
10.1.2.4. Growth Factors
10.1.2.5. Fusion Proteins
10.1.2.6.  Gene and Cellular Therapies
10.1.2.7. Insulin
10.1.2.8. Interferon
10.1.2.9. Monoclonal Antibody
10.2. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Rational Protein Design
10.2.2. Directed Evolution
10.2.3. Hybrid Approach
10.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Biopharmaceutical Companies
10.3.2. Academic Research Institutes
10.3.3. Contract Research Organizations (CROs)
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Protein Engineering Market – Opportunity Analysis Index, By Product Type, Technology, End User, and Country, 2022 – 2028
10.6. Europe Protein Engineering Market Dynamics – Trends
11. Asia-Pacific Protein Engineering Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
11.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.1.1. Vaccines
11.1.1.1. Live-attenuated Vacciness
11.1.1.2. Inactivated Vacciness
11.1.1.3. Recombinant protein Vacciness
11.1.1.4. Polysaccharide-based Vacciness
11.1.1.5. Messenger RNA Vacciness
11.1.2. Biologics
11.1.2.1. Hormones
11.1.2.2. Blood Products
11.1.2.3. Cytokines
11.1.2.4. Growth Factors
11.1.2.5. Fusion Proteins
11.1.2.6.  Gene and Cellular Therapies
11.1.2.7. Insulin
11.1.2.8. Interferon
11.1.2.9. Monoclonal Antibody
11.2. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Rational Protein Design
11.2.2. Directed Evolution
11.2.3. Hybrid Approach
11.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Biopharmaceutical Companies
11.3.2. Academic Research Institutes
11.3.3. Contract Research Organizations (CROs)
11.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Rest of Asia-Pacific
11.5. Asia-Pacific Protein Engineering Market – Opportunity Analysis Index, By Product Type, Technology, End User, and Country, 2022 – 2028
11.6. Asia-Pacific Protein Engineering Market Dynamics – Trends
12. Latin America Protein Engineering Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
12.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.1.1. Vaccines
12.1.1.1. Live-attenuated Vacciness
12.1.1.2. Inactivated Vacciness
12.1.1.3. Recombinant protein Vacciness
12.1.1.4. Polysaccharide-based Vacciness
12.1.1.5. Messenger RNA Vacciness
12.1.2. Biologics
12.1.2.1. Hormones
12.1.2.2. Blood Products
12.1.2.3. Cytokines
12.1.2.4. Growth Factors
12.1.2.5. Fusion Proteins
12.1.2.6.  Gene and Cellular Therapies
12.1.2.7. Insulin
12.1.2.8. Interferon
12.1.2.9. Monoclonal Antibody
12.2. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Rational Protein Design
12.2.2. Directed Evolution
12.2.3. Hybrid Approach
12.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Biopharmaceutical Companies
12.3.2. Academic Research Institutes
12.3.3. Contract Research Organizations (CROs)
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Argentina
12.4.3. Rest of Latin America
12.5. Latin America Protein Engineering Market – Opportunity Analysis Index, By Product Type, Technology, End User, and Country, 2022 – 2028
12.6. Latin America Protein Engineering Market Dynamics – Trends
13. Middle East and Africa Protein Engineering Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
13.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.1.1. Vaccines
13.1.1.1. Live-attenuated Vacciness
13.1.1.2. Inactivated Vacciness
13.1.1.3. Recombinant protein Vacciness
13.1.1.4. Polysaccharide-based Vacciness
13.1.1.5. Messenger RNA Vacciness
13.1.2. Biologics
13.1.2.1. Hormones
13.1.2.2. Blood Products
13.1.2.3. Cytokines
13.1.2.4. Growth Factors
13.1.2.5. Fusion Proteins
13.1.2.6.  Gene and Cellular Therapies
13.1.2.7. Insulin
13.1.2.8. Interferon
13.1.2.9. Monoclonal Antibody
13.2. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Rational Protein Design
13.2.2. Directed Evolution
13.2.3. Hybrid Approach
13.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Biopharmaceutical Companies
13.3.2. Academic Research Institutes
13.3.3. Contract Research Organizations (CROs)
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Saudi Arabia
13.4.2. GCC Countries
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Protein Engineering Market – Opportunity Analysis Index, By Product Type, Technology, End User, and Country, 2022 – 2028
13.6. MEA Protein Engineering Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product Type Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. GE Healthcare
14.2.2. Codexis, Inc.
14.2.3. Agilent Technologies, Inc.
14.2.4. Thermo Fisher Scientific, Inc.
14.2.5. Agilent Technologies, Inc.
14.2.6. Danaher Corporation
14.2.7. Abzena Ltd.
14.2.8. Genscript Biotech Corporation
14.2.9. Bio-Rad Laboratories
14.2.10. Sanofi
15. Research Methodology
16. Key Assumptions and Acronyms

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX